AZD6765 Oral Single Ascending Dose/Multiple Ascending Dose (SAD/MAD)

AstraZeneca

Status and phase: Withdrawn; Phase 1

Conditions: Healthy

Treatments: Drug: AZD6765

Study type: Interventional

Funder types: Industry

Identifiers

NCT00963365

D6703C00001

Details and patient eligibility

About

The purpose of this study is to determine the safety of AZD6765 when given in single and multiple oral doses and to compare an oral and intravenous (IV) formulation of AZD6765 to placebo.

Sex: All

Ages: 18 to 65 years old

Volunteers: Accepts Healthy Volunteers

Inclusion criteria

• Healthy volunteers
• Females must be of non-childbearing potential.

Exclusion criteria

• Any clinically significant illness, medical/surgical procedure or trauma within 4 weeks of the first administration of investigational product.
• Has received another new chemical entity (defined as a compound which has not been approved for marketing) or has participated in any other clinical study that included drug treatment within 3 months (if half-life was < 24 hours) of the first administration of study drug
• Plasma or blood product donation within one month of screening or any blood donation/blood loss > 500mL during the 3 months prior to screening.

Trial design

0 participants in 4 patient groups, including a placebo group

AZD6765 oral solution

Experimental group

Description:

Active

Treatment:

Drug: AZD6765

Drug: AZD6765

AZD6765 IV infusion

Experimental group

Description:

Active

Treatment:

Drug: AZD6765

Drug: AZD6765

Placebo to AZD6765 oral solution

Placebo Comparator group

Description:

Placebo

Treatment:

Drug: AZD6765

Drug: AZD6765

Placebo to AZD6765 IV infusion

Placebo Comparator group

Description:

Placebo

Treatment:

Drug: AZD6765

Drug: AZD6765